In this post hoc cohort study, cNfH levels were associated with clinical progression and baseline levels of CSF biomarkers (ie, α-synuclein, Aβ42, P-tau, and T-tau) in patients with PD. The gene discussed is MAPT; the disease is Parkinson disease.